177 related articles for article (PubMed ID: 15170907)
1. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
Haraoui B
J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
[No Abstract] [Full Text] [Related]
2. Anti-tumour necrosis factor agents and lipid profile: a class effect?
Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
[No Abstract] [Full Text] [Related]
3. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
Yelin E; Katz P
Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
[No Abstract] [Full Text] [Related]
4. Tumor necrosis factor-alpha blocker induced tuberculosis.
Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
[No Abstract] [Full Text] [Related]
5. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
Mariette X
Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
[No Abstract] [Full Text] [Related]
6. [Biological treatment of rhematoid diseases].
Pavelka K
Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
[No Abstract] [Full Text] [Related]
7. Advances in targeted therapies X. Preface.
Breedveld FC; Kalden JR; Smolen JS
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii1. PubMed ID: 19022807
[No Abstract] [Full Text] [Related]
8. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
9. [Non-TNF biologicals in therapy].
Wollenhaupt J; Burmester GR
Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
[No Abstract] [Full Text] [Related]
10. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
11. Infection and anti-tumor necrosis factor-alpha therapy.
Zandman-Goddard G
Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
[No Abstract] [Full Text] [Related]
12. Rheumatoid vasculitis treated with infliximab.
van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
[TBL] [Abstract][Full Text] [Related]
13. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
Winger EE; Reed JL
J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224
[No Abstract] [Full Text] [Related]
14. Advances in targeted therapies XI.
Breedveld FC; Kalden JR; Smolen JS
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i1. PubMed ID: 19995739
[No Abstract] [Full Text] [Related]
15. Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge.
Keane J; Ní Cheallaigh C
J Rheumatol; 2008 Jul; 35(7):1238-9. PubMed ID: 18597413
[No Abstract] [Full Text] [Related]
16. [Pregnancy in rheumatic patients treated with biologic drugs].
Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N
Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033
[No Abstract] [Full Text] [Related]
17. [Biological treatment of rheumatic diseases].
Procházková L; Böhmová J; Soucek M
Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
[TBL] [Abstract][Full Text] [Related]
18. TNF antagonists and shingles: is vaccination advisable?
Nisar MK; Ostor AJ
Ann Rheum Dis; 2013 May; 72(5):e1. PubMed ID: 23456927
[No Abstract] [Full Text] [Related]
19. Tuberculosis associated with therapy against tumor necrosis factor alpha.
Winthrop KL; Siegel JN; Jereb J; Taylor Z; Iademarco MF
Arthritis Rheum; 2005 Oct; 52(10):2968-74. PubMed ID: 16200576
[No Abstract] [Full Text] [Related]
20. Neurological complications of infliximab.
Tektonidou MG
J Rheumatol; 2007 Jan; 34(1):237; author reply 237-8. PubMed ID: 17216701
[No Abstract] [Full Text] [Related]
[Next] [New Search]